Relationship of frontal D(2/3) binding potentials to cognition: a study of antipsychotic-naive schizophrenia patients

The International Journal of Neuropsychopharmacology
Birgitte FagerlundBirte Y Glenthøj


Studies of in vivo dopamine receptors in schizophrenia have mostly focused on D(2) receptors in striatal areas or on D(1) receptors in cortex. No previous study has examined the correlation between cortical dopamine D(2/3) receptor binding potentials and cognition in schizophrenia patients. The objective was to examine this relation in the frontal cortex in first-episode, drug-naive schizophrenia patients. Based on preclinical and pharmacological evidence, we specifically expected to find a relation between D(2/3) receptor binding potentials and set shifting. This was a cross-sectional, case-control study using single-photon emission computerized tomography with the D(2/3)-receptor ligand [(123)I]epidepride, co-registered with structural magnetic resonance imaging and correlated to cognitive measures. Participants were 24 antipsychotic-naive, first-episode schizophrenia patients and 20 healthy controls matched for gender and age. For patients, a significant linear correlation between D(2/3) BP(ND) and set shifting was found, while significant quadratic associations were observed for verbal fluency, planning and attention. For controls, the only significant association with D(2/3) BP(ND) was a quadratic partial correlation for s...Continue Reading


Oct 27, 2016·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Henrik Nørbak-EmigBjørn H Ebdrup


Feb 22, 1991·Science·T Sawaguchi, P S Goldman-Rakic
Apr 15, 1991·Biological Psychiatry·J GeddesP Pratt
Aug 17, 1995·Nature·Graham V Williams, P S Goldman-Rakic
Oct 1, 1994·Psychopharmacology·Amy F T ArnstenP S Goldman-Rakic
Mar 30, 2000·The American Journal of Psychiatry·R M BilderJ A Lieberman
Mar 30, 2000·The American Journal of Psychiatry·L BäckmanLars Farde
Feb 7, 2001·Archives of General Psychiatry·R K HeatonD V Jeste
Jan 12, 2002·Archives of General Psychiatry·Tetsuya SuharaLars Farde
Nov 8, 2003·The International Journal of Neuropsychopharmacology·Mirjam TalvikLars Farde
Jun 1, 2004·The American Journal of Psychiatry·Fumihiko YasunoLars Farde
Sep 24, 2004·Progress in Neurobiology·Jeremy K Seamans, Charles R Yang
Oct 12, 2004·Schizophrenia Research·Karmen K YoderAnantha Shekhar
Apr 28, 2005·Psychiatry Research·Fumihiko YasunoMakoto Inoue
Jul 14, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Stan B FlorescoMaric T L Tse
Mar 2, 2006·Pharmacopsychiatry·A Carlsson
May 4, 2006·Psychopharmacology·Stan B Floresco, Orsolya Magyar
May 10, 2006·Biological Psychiatry·Vanessa L CropleyPradeep J Nathan
May 23, 2006·Schizophrenia Research·Monte S BuchsbaumJogeshwar Mukherjee
Jun 20, 2006·European Archives of Psychiatry and Clinical Neuroscience·Heli TuppurainenJari Tiihonen
Feb 6, 2007·Nature Neuroscience·Susheel VijayraghavanAmy F T Arnsten
May 24, 2007·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Robert B InnisRichard E Carson
Apr 3, 2008·The American Journal of Psychiatry·Gerhard GründerIngo Vernaleken

Related Concepts

Prevalence Studies
Antipsychotic Effect
Cortex Bone Disorders
Adrenal Cortex Diseases
Tomography, Emission-Computed, Single-Photon
Dopamine D3 receptor
Magnetic Resonance Imaging
Dopamine D2 Receptor
Plasma Protein Binding Capacity

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here